Mesenchymal lineage stem cells have pronounced anti-inflammatory effects in the twitcher mouse model of Krabbe's disease

Stem Cells

Volumn 29, Issue 1, 2011, Pages 67-77

  Ripoll, Cynthia B ^a,b   Flaat, Mette ^b   Klopf Eiermann, Jessica ^a   Fisher Perkins, Jeanne M ^a   Trygg, Cynthia B ^a   Scruggs, Brittni A ^b   McCants, Marjorie L ^b   Leonard, Helen Paige ^b   Lin, Amy F ^b   Zhang, Shijia ^b   Eagle, Michelle E ^a   Alvarez, Xavier ^a   Li, Yu Teh ^b   Li, Su Chen ^b   Gimble, Jeffrey M ^c   Bunnell, Bruce A ^a,b  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Adipose tissue; Bone marrow; Globoid cell leukodystrophy; Krabbe's disease; Stem cells; Therapy; Twitcher mouse

Indexed keywords

MARKER; MYELIN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; BONE MARROW CELL; CELL ACTIVATION; CELL INFILTRATION; CELL LINEAGE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; GLOBOID CELL LEUKODYSTROPHY; INFLAMMATION; LIFESPAN; MACROPHAGE; MESENCHYMAL STEM CELL; MICROGLIA; MOTOR PERFORMANCE; MOUSE; NEWBORN; NONHUMAN; PATHOLOGY; PERINATAL PERIOD; SURVIVAL;

ADIPOSE TISSUE; ANIMALS; BONE MARROW; CELL LINEAGE; DISEASE MODELS, ANIMAL; GALACTOSYLCERAMIDASE; GENE EXPRESSION PROFILING; GREEN FLUORESCENT PROTEINS; HUMANS; INFLAMMATION; LEUKODYSTROPHY, GLOBOID CELL; LYSOSOMES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE II;

ANIMALIA; MUS;

EID: 79951849190     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.555     Document Type: Article

References (60)

1. Suzuki K, Suzuki Y. Globoid cell leucodystrophy (Krabbe's disease): Deficiency of galactocerebroside beta-galactosidase. Proc Natl Acad Sci USA 1970;66:302-309.
2. Wenger DA, Rafi MA, Luzi P. Molecular genetics of Krabbe disease (globoid cell leukodystrophy): Diagnostic and clinical implications. Hum Mutat 1997;10:268-279. (Pubitemid 27430501)
3. Svennerholm L, Vanier MT, Mansson JE. Krabbe disease: A galactosylsphingosine (psychosine) lipidosis. J Lipid Res 1980;21:53-64. (Pubitemid 10120438)
4. Igisu H, Suzuki K. Progressive accumulation of toxic metabolite in a genetic leukodystrophy. Science 1984;224:753-755. (Pubitemid 14140043)
5. Taniike M, Mohri I, Eguchi N et al. An apoptotic depletion of oligodendrocytes in the twitcher, a murine model of globoid cell leukodystrophy. J Neuropathol Exp Neurol 1999;58:644-653. (Pubitemid 29264944)
6. Dolcetta D, Perani L, Givogri MI et al. Design and optimization of lentiviral vectors for transfer of GALC expression in Twitcher brain. J Gene Med 2006;8:962-971. (Pubitemid 44282992)
7. Wenger DA, Rafi MA, Luzi P et al. Krabbe disease: Genetic aspects and progress toward therapy. Mol Genet Metab 2000;70:1-9. (Pubitemid 30396199)
8. Escolar ML, Poe MD, Provenzale JM et al. Transplantation of umbilical- cord blood in babies with infantile Krabbe's disease. N Engl J Med 2005;352:2069-2081. (Pubitemid 40664308)
9. Duffner PK, Caviness VS Jr., Erbe RW et al. The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: Report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York. Genet Med 2009;11:450-454.
10. Kobayashi T, Yamanaka T, Jacobs JM et al. The Twitcher mouse: An enzymatically authentic model of human globoid cell leukodystrophy (Krabbe disease). Brain Res 1980;202:479-483.
11. Suzuki K. The twitcher mouse: A model for Krabbe disease and for experimental therapies. Brain Pathol 1995;5:249-258.
12. Lin D, Donsante A, Macauley S et al. Central nervous system-directed AAV2/5-mediated gene therapy synergizes with bone marrow transplantation in the murine model of globoid-cell leukodystrophy. Mol Ther 2007;15:44-52. (Pubitemid 46043648)
13. Pellegatta S, Tunici P, Poliani PL et al. The therapeutic potential of neural stem/progenitor cells in murine globoid cell leukodystrophy is conditioned by macrophage/microglia activation. Neurobiol Dis 2006;21:314-323. (Pubitemid 43099855)
14. Yeager AM, Brennan S, Tiffany C et al. Prolonged survival and remyelination after hematopoietic cell transplantation in the twitcher mouse. Science 1984;225:1052-1054. (Pubitemid 14066323)
15. Hoogerbrugge PM, Poorthuis BJ, Romme AE et al. Effect of bone marrow transplantation on enzyme levels and clinical course in the neurologically affected twitcher mouse. J Clin Invest 1988;81:1790-1794.
16. Suzuki K, Hoogerbrugge PM, Poorthuis BJ et al. The twitcher mouse. Central nervous system pathology after bone marrow transplantation. Lab Invest 1988;58:302-309.
17. Lee WC, Courtenay A, Troendle FJ et al. Enzyme replacement therapy results in substantial improvements in early clinical phenotype in a mouse model of globoid cell leukodystrophy. FASEB J 2005;19:1549-1551. (Pubitemid 41279027)
18. Shen JS, Watabe K, Ohashi T et al. Intraventricular administration of recombinant adenovirus to neonatal twitcher mouse leads to clinicopathological improvements. Gene Ther 2001;8:1081-1087. (Pubitemid 32962705)
19. Torchiana E, Lulli L, Cattaneo E et al. Retroviral-mediated transfer of the galactocerebrosidase gene in neural progenitor cells. NeuroReport 1998;9:3823-3827. (Pubitemid 29189310)
20. Taylor RM, Lee JP, Palacino JJ et al. Intrinsic resistance of neural stem cells to toxic metabolites may make them well suited for cell non-autonomous disorders: Evidence from a mouse model of Krabbe leukodystrophy. J Neurochem 2006;97:1585-1599. (Pubitemid 43873654)
21. Meng XL, Shen JS, Watabe K et al. GALC transduction leads to morphological improvement of the twitcher oligodendrocytes in vivo. Mol Genet Metab 2005;84:332-343. (Pubitemid 40386880)
22. Lin D, Fantz CR, Levy B et al. AAV2/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2. Mol Ther 2005;12:422-430. (Pubitemid 41150127)
23. Croitoru-Lamoury J, Williams KR, Lamoury FM et al. Neural transplantation of human MSC and NT2 cells in the twitcher mouse model. Cytotherapy 2006;8:445-458. (Pubitemid 44596997)
24. Biswas S, Biesiada H, Williams TD et al. Substrate reduction intervention by L-cycloserine in twitcher mice (globoid cell leukodystrophy) on a B6;CAST/Ei background. Neurosci Lett 2003;347:33-36. (Pubitemid 36831100)
25. Biswas S, LeVine SM. Substrate-reduction therapy enhances the benefits of bone marrow transplantation in young mice with globoid cell leukodystrophy. Pediatr Res 2002;51:40-47. (Pubitemid 34008208)
26. Galbiati F, Givogri MI, Cantuti L et al. Combined hematopoietic and lentiviral gene-transfer therapies in newborn Twitcher mice reveal contemporaneous neurodegeneration and demyelination in Krabbe disease. J Neurosci Res 2009;87:1748-1759.
27. Puissant B, Barreau C, Bourin P et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: Comparison with bone marrow mesenchymal stem cells. Br J Haematol 2005;129:118-129. (Pubitemid 40524060)
28. Le Blanc K, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:321-334. (Pubitemid 40542924)
29. Le Blanc K, Ringden O. Mesenchymal stem cells: Properties and role in clinical bone marrow transplantation. Curr Opin Immunol 2006;18:586-591. (Pubitemid 44311450)
30. Porada CD, Zanjani ED, Almeida-Porad G. Adult mesenchymal stem cells: A pluripotent population with multiple applications. Curr Stem Cell Res Ther 2006;1:365-369.
31. Ringden O, Uzunel M, Rasmusson I et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006;81:1390-1397. (Pubitemid 43847148)
32. McIntosh K, Zvonic S, Garrett S et al. The immunogenicity of human adipose-derived cells: Temporal changes in vitro. Stem Cells 2006;24:1246-1253. (Pubitemid 44464693)
33. Yanez R, Lamana ML, Garcia-Castro J et al. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 2006;24:2582-2591. (Pubitemid 44674320)
34. Mahmood A, Lu D, Chopp M. Marrow stromal cell transplantation after traumatic brain injury promotes cellular proliferation within the brain. Neurosurgery 2004;55:1185-1193.
35. Chen X, Armstrong MA, Li G. Mesenchymal stem cells in immunoregulation. Immunol Cell Biol 2006;84:413-421. (Pubitemid 44286034)
36. Gonzalez MA, Gonzalez-Rey E, Rico L et al. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 2009;136:978-989.
37. Gonzalez MA, Gonzalez-Rey E, Rico L et al. Treatment of experimental arthritis by inducing immune tolerance with human adiposederived mesenchymal stem cells. Arthritis Rheum 2009;60:1006-1019.
38. Gonzalez-Rey E, Anderson P, Gonzalez MA et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009;58:929-939.
39. Prockop DJ. Repair of tissues by adult stem/progenitor cells (MSCs): Controversies, myths, and changing paradigms. Mol Ther 2009;17:939-946.
40. Wu YP, McMahon EJ, Matsuda J et al. Expression of immune-related molecules is downregulated in twitcher mice following bone marrow transplantation. J Neuropathol Exp Neurol 2001;60:1062-1074. (Pubitemid 33021440)
41. Giri S, Jatana M, Rattan R et al. Galactosylsphingosine (psychosine)-induced expression of cytokine-mediated inducible nitric oxide synthases via AP-1 and C/EBP: Implications for Krabbe disease. FASEB J 2002;16:661-672. (Pubitemid 34465430)
42. Kagitani-Shimono K, Mohri I, Fujitani Y et al. Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model. J Neuroinflammation 2005;2:10.
43. Formichi P, Radi E, Battisti C et al. Psychosine-induced apoptosis and cytokine activation in immune peripheral cells of Krabbe patients. J Cell Physiol 2007;212:737-743. (Pubitemid 47267542)
44. Borda JT, Alvarez X, Mohan M et al. Clinical and immunopathologic alterations in rhesus macaques affected with globoid cell leukodystrophy. Am J Pathol 2008;172:98-111. (Pubitemid 351186372)
45. Ripoll CB, Bunnell BA. Comparative characterization of mesenchymal stem cells from eGFP transgenic and non-transgenic mice. BMC Cell Biol 2009;10:3.
46. Matsushima GK, Taniike M, Glimcher LH et al. Absence of MHC class II molecules reduces CNS demyelination, microglial/macrophage infiltration, and twitching in murine globoid cell leukodystrophy. Cell 1994;78:645-656. (Pubitemid 24268587)
47. Raghavan S, Krusell A. Optimal assay conditions for enzymatic characterization of homozygous and heterozygous twitcher mouse. Biochim Biophys Acta 1986;877:1-8. (Pubitemid 16060187)
48. Hawkes CA, McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc Natl Acad Sci USA 2009;106:1261-1266.
49. Luzi P, Abraham RM, Rafi MA et al. Effects of treatments on inflammatory and apoptotic markers in the CNS of mice with globoid cell leukodystrophy. Brain Res 2009;1300:146-158.
50. Nathan C. Inducible nitric oxide synthase: What difference does it make? J Clin Invest 1997;100:2417-2423.
51. Laroux FS, Pavlick KP, Hines IN et al. Role of nitric oxide in inflammation. Acta Physiol Scand 2001;173:113-118. (Pubitemid 32948340)
52. Nathan C, Calingasan N, Nezezon J et al. Protection from Alzheimer's- like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J Exp Med 2005;202:1163-1169. (Pubitemid 41586946)
53. Ren G, Zhang L, Zhao X et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008;2:141-150. (Pubitemid 351181031)
54. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8:726-736.
55. Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99:3838-3843. (Pubitemid 34534559)
56. Groh ME, Maitra B, Szekely E et al. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 2005;33:928-934. (Pubitemid 40982660)
57. Djouad F, Charbonnier LM, Bouffi C et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007;25:2025-2032. (Pubitemid 47258180)
58. Selmani Z, Naji A, Zidi I et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008;26: 212-222.
59. Krampera M, Cosmi L, Angeli R et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006;24:386-398. (Pubitemid 44464808)
60. Ren G, Su J, Zhang L et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009;27:1954-1962.